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Assisted Reproductive Technology in Europe: 
Usage and Regulation in the Context 
of Cross-Border Reproductive Care
Patrick Präg and Melinda C. Mills
14.1  Introduction
Involuntary childlessness, or infertility, is a condition that affects a sizeable number 
of couples around the world (Mascarenhas et al. 2012). Assisted reproductive tech-
nologies (ART) represent an important set of techniques for addressing involuntary 
childlessness. While it has always been difficult to make a precise distinction 
between voluntary and involuntary childlessness, the main reasons for childless-
ness, such as the perceived lack of a suitable partner or problems associated with 
balancing work and family, can be seen as both voluntary and involuntary (Sobotka 
2010). The current trend of fertility postponement in European societies (Mills et al. 
2011) has exacerbated the issue of involuntary childlessness. While it is clear that 
female fecundity declines sharply at higher ages, because the pace of fecundity loss 
varies greatly between women, it can be difficult for an individual woman to ascer-
tain how long she can postpone childbearing (te Velde and Pearson 2002; te Velde 
et al. 2012).
ART is increasingly perceived as being one way to alleviate the problems of 
involuntary childlessness. Between the birth in 1978 of Louise Brown, the first live 
ART baby (Steptoe and Edwards 1978), and the awarding of the Nobel Prize in 
Physiology or Medicine to Robert G. Edwards for the development of in vitro fertil-
ization in 2010, ART had become a standard medical practice and a profitable com-
mercial enterprise for thousands of firms in Europe. An estimated five million 
babies have been born with the help of assisted reproduction in the past four decades 
(Adamson et al. 2013), a sizable share of them in Europe.
ART generally refers to treatments in which gametes or embryos are handled in 
vitro (“in glass;” i.e., outside of the body) to establish a pregnancy. A key technique 
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of ART is in vitro fertilization (IVF). In IVF, oocytes are fertilized using sperm in a 
laboratory and the embryo is surgically implanted in the woman’s womb. IVF was 
invented to treat cases of female infertility. When only a single sperm cell is injected 
into the oocyte during IVF, the procedure is referred to as intracytoplasmic sperm 
injection (ICSI). ICSI was developed to tackle male fertility problems, such as a low 
sperm count or poor sperm quality, but has in recent years become a standard form 
of fertilization in ART. A frozen or thawed embryo transfer is an IVF procedure in 
which embryos that have been cryopreserved for storage are transferred (as opposed 
to a “fresh” transfer of never-frozen embryos). This procedure is often used because 
obtaining oocytes from a woman is a rather invasive act. Thus, after a hormonal 
treatment, several oocytes are collected at the same time, fertilized, and frozen for 
later use in case the first embryo transfer fails—which is likely, given the relatively 
low success rate of ART (Malizia et al. 2009). In an alternative collection strategy, 
immature eggs are collected from a woman and are then matured in a lab (in vitro 
maturation). This procedure may be indicated when a woman is at risk of reacting 
adversely to the fertility drugs given before the oocytes are collected.
Frozen oocyte replacement is a technique in which oocytes are retrieved, frozen, 
stored (oocyte cryopreservation), and fertilized only after they have been thawed for 
transfer. This technique provides women with the option of having genetically 
related children later in life, even if no suitable father is present at the time of cryo-
preservation. Frozen oocyte replacement was first used in cancer patients, who had 
oocytes retrieved and frozen before undergoing forms of chemo- or radiotherapy 
that could damage their ovaries. But because this technique can also be used for 
delaying motherhood for any reason, including the desire to pursue a career, it has 
attracted substantial public attention in recent years, and is sometimes referred to as 
“social freezing” (Mertes and Pennings 2011). Large companies, such as Facebook 
and Apple, have recently offered social freezing as a benefit for female employees, 
offering them up to $20,000 to cover the cost of egg freezing (Tran 2014).
When prospective parents are concerned about passing on hereditary diseases 
like cystic fibrosis, it can be useful to conduct preimplantation genetic diagnosis 
(PGD) or screening (PGS). PGD involves examining an embryo to determine 
whether specific genetic and structural alterations are present. In PGS, an embryo is 
examined to ascertain whether any aneuploidy, mutation, or DNA rearrangement 
has taken place. In cases of egg donation, an oocyte from a woman is fertilized and 
then transferred to another woman’s womb. Donation may be done in cases of sur-
rogate motherhood for prospective parents who are unable to carry a child, such as 
a gay male couple; or when a woman is unable to have her own oocytes fertilized, 
often because she is older. Another type of egg donation is called “egg sharing:” 
women who underwent ART can share any non-used frozen oocyte with other 
women, sometimes in exchange for a discount on their ART treatments.
Globally, Europe has the largest number of ART treatments. In 2005, the most 
recent year for which global data are available, 56 % of ART aspirations1 were in 
1 Aspirations are initiated ART cycles in which one or more follicles are punctured and aspirated, 
irrespective of whether oocytes are retrieved. See Footnote 2 for more details on the metrics with 
which ART treatments are recorded.
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Europe, 23 % were in Asia, and 15 % were in North America (Zegers-Hochschild 
et al. 2014). As many European countries have been characterized as having 
“lowest- low” fertility (Kohler et al. 2002), ART represents not just a means of alle-
viating the suffering of individuals who are involuntarily childless, but also a poten-
tial policy lever for raising fertility rates in Europe. Thus, there is substantial interest 
in ART among policy-makers. Another key aspect of ART in Europe is the stark 
variation in the rates of ART uptake and in the regulation of ART, both across coun-
tries and over time. This variation in regulations between and within European 
countries allows us to make comparisons that could yield important insights into the 
antecedents and outcomes of ART usage and could have implications for ART 
across the globe.
The first aim of the current study is to present comparative data on ART usage in 
Europe, demonstrating the wide variability across European countries. In a second 
step, we will explore forms of ART governance across European countries, illustrat-
ing the variation in how ART is regulated and in who gets access to which tech-
niques. We then turn to the specific case of surrogacy, which often falls outside the 
scope of national ART legislation. We conclude with a related discussion on cross-
border reproductive care, which is sometimes characterized as “reproductive tour-
ism.” In the concluding section, we will summarize the findings, discuss the 
implications, and point to areas for future research.
14.2  Usage of Assisted Reproductive Technologies 
in European Countries
The usage of ART varies considerably across European countries. Although diag-
nostic and treatment services are currently available in all European countries, the 
variation in ART usage indicates that there are substantial differences in equity of 
access. To explore these differences, we analyze data collected by the European IVF 
Monitoring (EIM) Consortium of the European Society of Human Reproduction 
and Embryology (ESHRE). The EIM data go back to 1997, and are based on infor-
mation from national registries (with the voluntary or mandatory participation) of 
European countries; or, if those are not available, stem from information reported by 
clinics. In our analysis, we primarily focus on information from the most recent 
report, which contains data for the year 2010 (Kupka et al. 2014), and present infor-
mation from the countries that have complete or almost complete figures.
In Fig. 14.1, we can see the high degree of variation in ART usage across Europe. 
The figure shows the number of treatments2 by the main group of potential ART 
2 There are different metrics for recording ART treatments. The term “initiated ART cycle” refers 
to the menstrual cycle in which a woman receives ovarian stimulation (or, in the rare case of natu-
ral-cycle IVF, receives monitoring) with the intention of conducting ART, regardless of whether a 
follicular aspiration is attempted. The term “aspiration” refers to an attempt to retrieve oocytes 
from one or more follicles, regardless of whether oocytes are successfully retrieved. The term 
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patients in a country; namely, women between the ages of 15 and 45. Denmark, 
Belgium, Iceland, Sweden, and Slovenia are the countries where the largest num-
bers of ART cycles are initiated. A comparison of these four countries shows that 
there is substantial heterogeneity at the top of the distribution. ART treatments are 
considerably more common in Belgium and Denmark than in Iceland, Sweden, and 
Slovenia. It is also striking that the top group is not completely dominated by afflu-
ent western European countries. In addition to Slovenia, the Czech Republic, 
Estonia, and Serbia are also in the upper half of the distribution; well ahead of 
wealthy nations such as Switzerland, the Netherlands, or Germany. When we look 
at the bottom of the distribution, it is apparent that ART is no more widespread in 
Germany, Austria, or Ireland than it is in Ukraine or in Albania.
A number of studies have attempted to explain the very large differences in ART 
usage across countries. Several factors have emerged. ART costs and affordability 
appear to play an important role. Belgium and Denmark are known for their 
 comparatively generous reimbursement policies for couples and individuals under-
“transfer” refers to a procedure in which embryos are placed in the uterus or Fallopian tube, irre-
spective of whether a pregnancy is achieved (Zegers-Hochschild et al. 2009). However, for frozen 
embryo replacements, frozen oocyte replacements, and egg donations, cycles and aspirations are 
usually not recorded; here, thawings and transfers are the relevant metrics.
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Fig. 14.1 ART cycles per million women age 15–45 per country, 2010 (Sources: Ferraretti et al. 
(2012, 2013) and Kupka et al. (2014). Notes: The values for Albania, Estonia, Ireland, Lithuania, 
Poland, Spain, Serbia, Switzerland, and Ukraine refer to 2008; the values for Croatia, Cyprus, and 
France, and Denmark refer to 2009. ART cycles include IVF, ICSI, frozen embryo replacement 
(thawings), preimplantation genetic diagnosis and screening, egg donation (donation cycles), 
in vitro maturation, and frozen oocyte replacement (thawings))
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going ART. In a cross-national study, Chambers et al. (2014) found that greater 
affordability of ART—measured as the net cost of an ART cycle in a country as a 
share of the average disposable income in that country—is associated with greater 
ART utilization. Remarkably, this finding holds even after accounting for important 
factors such as GDP per capita, the number of physicians, and the number of ART 
clinics in a country. Studies that have looked at variation within countries and over 
time (e.g., Hamilton and McManus 2012) have also found evidence that affordabil-
ity is an important driver not only of utilization, but also of the use of safer ART 
practices.
Norms and beliefs also seem to play an important role for cross-national differ-
ences in ART usage. Billari et al. (2011) found that there is a large positive associa-
tion between higher social age deadlines for childbearing—i.e., generally shared 
assumptions about when one is too old to have children—and the availability of 
ART in European countries. The higher the social age norm for childbearing, the 
greater the availability of ART clinics. Kocourkova et al. (2014) showed that ART 
use and the total fertility rate in a country are correlated, which they interpret as 
being a sign of increasing demand for children. This interpretation is plausible, as 
most studies have found that the net impact of ART on fertility rates is actually 
small (Präg et al. 2015). Mills and Präg (2015) have suggested that beliefs about the 
moral status of a fertilized egg—i.e., whether a human embryo is seen as a human 
being immediately after fertilization—are associated with ART utilization. 
Generally, in countries where the belief that an embryo becomes a human being 
right after fertilization is less widespread, ART is used more often.
In addition to the differences in the extent of ART usage in Europe, there is also 
considerable variation in the range of ART techniques that are utilized. Figure 14.2 
reports the share of single ART treatments among all ART treatments for selected 
countries in 2010. The classical form of ART, in vitro fertilization, is no longer the 
most popular type of ART procedure. The share of IVF treatments among all ART 
treatments ranges from less than 10 % in Spain to slightly more than 40 % in 
Denmark. ICSI, a method invented more recently (Palermo et al. 1992) to treat male 
factor infertility, has overtaken IVF in recent years as the method of choice for ART 
(Kupka et al. 2014). The reasons for this development are not fully understood, 
especially because the leading professional organizations of reproductive health 
providers discourage the routine practice of ICSI in the absence of male factor infer-
tility diagnoses (Boulet et al. 2015). It is likely related to what demographic 
researchers have called the “absent and problematic men” issue in fertility research 
and infertility diagnoses, as collecting data on men and establishing male factor 
infertility is difficult (Greene and Biddlecom 2000). Nonetheless, in virtually all of 
the countries displayed in Fig. 14.2, the share of ART procedures that are ICSI treat-
ments is larger than the share of procedures that are IVF treatments. Only in 
Denmark is the share of ART procedures that are IVF treatments slightly larger 
(42 %) than the share that are ICSI treatments (35 %). In the United Kingdom, IVF 
and ICSI are used to a similar extent (37 and 40 %, respectively). The substantial 
differences between countries have been noted in the literature, yet explanations for 
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these differences are still lacking (Nyboe Andersen et al. 2008). It is, however, clear 
that IVF and ICSI together make up the bulk of treatments in all countries.
The third-most popular form of ART treatment is frozen embryo replacement, 
making up between 6 % (Italy) and 31 % (Belgium) of ART treatments. The low 
uptake of FER in Italy is attributable to a national law that prohibited embryo cryo-
preservation (except under exceptional circumstances) from 2004 to 2009 
(Benagiano and Gianaroli 2010). The relative popularity of FER in Germany is 
surprising, as German regulations regarding embryo freezing are fairly restrictive: 
i.e., the non-emergency freezing of embryos is banned, and the freezing of fertilized 
eggs is allowed only in the earliest stages of development. Preimplantation genetic 
diagnosis (PGD), which has been practiced since the early 1990s (Simpson 2010), 
is likely the ethically most controversial form of ART. PGD has clear benefits, as it 
can help parents avoid passing on inheritable disorders to their children, and it is 
generally considered to be safe and to have a low rate of errors (Ory et al. 2014). 
However, fears about the creation of “designer babies” and moral concerns about 
the use of PGD for non-medical purposes (such as sex selection) are often expressed 
in public discussions about ART. The data show that very few ART procedures 
involve PGD: the share of all ART treatments in a country that involve PGD ranges 
from no reported cases (in Germany and Italy) to 4.7 % of cases (in Spain). The 
share is around 1 % in Denmark, Slovenia, and the United Kingdom; and is around 
2 % in Belgium and the Czech Republic. Given the controversy surrounding PGD, 
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Fig. 14.2 ART treatments in selected countries, 2010 (Notes: IVF in vitro fertilization (cycles), 
ICSI intracytoplasmic sperm injection (cycles), FER frozen embryo replacement (thawings), PGD 
preimplantation genetic diagnosis (cycles), ED egg donation (donations), FOR: frozen oocyte 
replacement (thawings). In vitro maturation (aspirations, 0.0–0.1 % per country) not displayed. 
Source: Kupka et al. (2014))
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it is interesting to note that the procedure is generally allowed in all of the countries 
listed in Fig. 14.2 (Ory et al. 2014); however, Denmark and Slovenia restrict its use 
to screening for specific hereditary disorders.
Egg donation is also a technique that is not practiced in all countries, as can be 
seen in Fig. 14.2. Germany and Italy report no cases, and in Slovenia and Denmark 
egg donation makes up less than 2 % of ART procedures. In the United Kingdom 
and Belgium, the shares are slightly higher (3.3 and 5 %, respectively). In the Czech 
Republic and Spain a significant share (9.7 and 22 %) of ART treatments involve 
egg donation. As we will discuss in more detail below, it is important to note that 
these differences between countries are attributable in part to cross-border repro-
ductive care. Couples and single women who are unable to obtain the desired treat-
ment in their home country are sometimes willing to travel abroad to obtain that 
treatment in another country. Frozen oocyte replacement (FOR), which builds on 
fertilizing thawed oocytes, is a relatively rare form of ART: FOR treatments are 
reported only in the United Kingdom, Spain, and Italy (0.1, 3.1, and 4.1 %, respec-
tively). One reason for the relative popularity of FOR in Italy is that the cryopre-
serving of embryos was banned, which created incentives to further develop and 
refine technologies for cryopreserving oocytes.
14.3  Regulation of Assisted Reproductive Technology 
in Europe
Europe is the only continent where the legal regulation of ART is widespread. Other 
major countries where ART is used, such as India, Japan, and the U.S., largely rely 
on voluntary guidelines. While ART regulation is sometimes portrayed as a novel 
phenomenon, there is a long history of government interference in the reproductive 
realm. For example, countries have long had laws pertaining to marriage and 
divorce, contraception, births out of wedlock, adoption, and abortion (Spar 2005).
There are three major ways of regulating the practice of and the access to 
ART. First, ART can be regulated via guidelines, or sets of rules that practitioners 
are expected to follow voluntarily. These guidelines are generally issued by profes-
sional organizations, such as associations of obstetricians and gynaecologists. 
Second, as an alternative or a supplement to these guidelines, ART is also often 
subject to governmental legislation. Thus, rules for using ART are codified in the 
law, and penalties for the violation of these rules are imposed. A third route that 
regulates access to ART is insurance coverage: given the high cost of infertility 
treatments, the level of coverage can be seen as an indirect regulation of access to 
ART. However, because infertility is now seen as a condition leading to disability 
(WHO and World Bank 2011), infertile individuals should have a right to 
treatment.
The International Federation of Fertility Societies (IFFS) provides information 
on ART guidelines, regulations, and insurance coverage in their triennial 
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“Surveillance Reports,” which have been published since 1999 (Jones and Cohen 
1999). The data in these reports are based on surveys of experts from national fertil-
ity societies. The IFFS data are organized into relatively broad categories, and are 
sometimes incomplete or inconsistent. Nonetheless, these reports provide a useful 
overview of the differences in ART governance across Europe. In the following, we 
present data from the most recent IFFS Surveillance Report (Ory et al. 2014), which 
refers to the year 2013. We include all of the European countries featured in the 
report, plus a number of contrasting non-European cases.
The left column of Table 14.1 reveals that in all European countries, ART is 
regulated under the law. In about half of the countries, governmental regulation is 
supplemented by voluntary guidelines. By contrast, for two of the three non- 
European cases listed at the bottom of the Table (India and Japan), ART is fully 
governed by voluntary guidelines. While the distinction between legislation and 
guidelines does not reveal the scope and extent of the actual regulation, it roughly 
illustrates how important ART is to the respective government. The second column 
shows that ART legislation is a salient issue for governments, as half of the coun-
tries have introduced new ART legislation in the relatively short period of 4 years.
When it comes to the financing of ART treatments, virtually all European coun-
tries offer some assistance. Only Belarus, Ireland, and Switzerland do not provide 
their citizens with any form of coverage. Whereas most countries provide coverage 
via national health plans, some mandate that private insurers provide coverage. Six 
countries—Denmark, France, Hungary, Russia, Slovenia, and Spain—offer com-
plete coverage through national health plans. A comparison with the results from 
Fig. 14.1 reveals that Denmark, Slovenia, and Spain are among the countries with 
particularly high ART utilization rates. In the countries where partial coverage is 
provided, the extent of the coverage varies considerably. For example, two-thirds of 
the costs are covered by the national health system in Austria, but only 40 % of the 
costs are covered in Finland. Furthermore, the level of insurance coverage usually 
depends on patient characteristics. In Spain, for example, coverage is only available 
for women up to age 40. Slovenia covers six cycles for the first child and four cycles 
after a first live birth, but only for women up to age 42. In some parts of the United 
Kingdom, women who are obese are being denied coverage. In the U.S., there is 
substantial heterogeneity in coverage across the states, with a few states providing 
rather generous coverage, and the vast majority providing no coverage.
Couple and sexuality requirements represent a socially relevant aspect of ART 
policies, as they govern access to ART treatments over and above the financial 
restrictions that infertile couples and individuals face. Table 14.2 lists the couple 
and sexuality requirements, as reported by Ory et al. (2014) for all European coun-
tries and India, Japan, and the U.S. It should be noted that these requirements can 
stem from both legislation and guidelines. The first column of Table 14.2 reveals 
that marriage is a requirement for ART treatment in most countries. Only six out of 
22 European countries in Table 14.2 report that marriage is not a requirement for 
ART access. However, apart from Turkey (and Japan), all of the European countries 
listed also provide treatment to couples who live in a stable relationship. Ory et al. 
(2014) acknowledged that “stable relationship” is a poorly defined concept open to 
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Table 14.1 Types of ART regulation in Europe, India, Japan, and the U.S., 2013
Country
Type of ART 
governance
New ART 
legislation since 
2009 Type of coverage
Extent of 
coverage
Austria Legislation and 
guidelines
No National health plan Partial
Belarus Legislation and 
guidelines
No No coverage None
Belgium Legislation only Yes National health plan 
and private 
insurance
Partial
Bulgaria Legislation only Yes National health plan Partial
Croatia Legislation only Yes National health plan 
and private 
insurance
Partial
Czech 
Republic
Legislation only Yes National health plan Partial
Denmark Legislation only Yes National health plan Complete
Finland Legislation only No National health plan Partial
France Legislation and 
guidelines
Yes National health plan Complete
Greece Legislation only No National health plan Partial
Hungary Legislation only No National health plan Complete
Iceland Legislation only No National health plan Partial
Ireland Legislation and 
guidelines
No No coverage None
Italy Legislation and 
guidelines
Yes National health plan Partial
Latvia Legislation and 
guidelines
Yes National health plan Partial
Norway Legislation and 
guidelines
No National health plan Partial
Portugal Legislation only Yes National health plan Partial
Russia Legislation and 
guidelines
Yes National health plan Complete
Slovenia Legislation only No National health plan Complete
Spain Legislation and 
guidelines
No National health plan 
and private 
insurance
Complete
Sweden Legislation and 
guidelines
No National health plan Partial
Switzerland Legislation and 
guidelines
No No coverage None
Turkey Legislation and 
guidelines
Yes National health plan Partial
United 
Kingdom
Legislation and 
guidelines
Yes Private insurance Partial
(continued)
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interpretation, yet it is widely embraced across countries. Countries are somewhat 
more restrictive in their rules regarding unpartnered women who want to undergo 
ART treatment. Only 10 of the 22 European countries, along with India and the 
U.S., permit singles to utilize ART services. Moreover, only seven European coun-
tries and the U.S. allow lesbian women to have access to ART.
Table 14.1 (continued)
Country
Type of ART 
governance
New ART 
legislation since 
2009 Type of coverage
Extent of 
coverage
India Guidelines only No No coverage None
Japan Guidelines only No National health plan Partial
United States Legislation and 
guidelines
No Private insurance Partial
Source: Ory et al. (2014)
Table 14.2 Couple and sexuality requirements for ART in Europe, India, Japan, and the U.S., 
2013
Marriage 
required
Stable relationship 
permitted
Singles 
permitted
Lesbians 
permitted
Austria Yes Yes No No
Belgium Yes Yes Yes Yes
Bulgaria Yes Yes Yes Yes
Croatia Yes Yes No No
Czech Republic Yes Yes No No
Denmark Yes Yes Yes Yes
Finland No Yes Yes Yes
France No Yes No No
Greece No Yes Yes No
Hungary Yes Yes Yes No
Ireland No Yes No No
Italy Yes Yes No No
Latvia Yes Yes Yes Yes
Russia Yes Yes Yes No
Slovenia No Yes No No
Spain Yes Yes Yes Yes
Sweden Yes Yes No No
Switzerland No Yes No No
Turkey Yes No No No
United Kingdom No Yes Yes Yes
India Yes Yes Yes No
Japan Yes No No No
United States No Yes Yes Yes
Source: Ory et al. (2014)
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To better illustrate how European countries vary in their approach to regulating 
forms of ART, we examine the particularly controversial ART variant of surrogacy. 
There are several forms of surrogacy (see the notes below Table 14.3). The most 
prominent form is a traditional variant that uses the surrogate mother’s egg. By 
contrast, in gestational surrogacy, the egg is provided by the intended mother or a 
donor, fertilized via IVF, and then transferred to the surrogate mother’s womb.
The first central difference between countries lies in whether they prohibit 
(Table 14.3, column 1) or heavily regulate surrogacy (Table 14.3, column 3). 
Surrogacy is prohibited in many countries, such as France, Germany, Italy, Spain, 
and Portugal. Surrogate motherhood is explicitly allowed in Belgium, Belarus, 
Denmark, Greece, Ireland, the Russian Federation, Ukraine, and the United 
Kingdom. A second difference refers to compensation of the surrogate mother. 
When surrogacy is permitted, in some countries the prospective parents are not 
allowed to pay the surrogate mother beyond covering her “altruistic costs.” 
Conversely, commercial surrogacy is legal in certain U.S. states, as well as in India, 
Ukraine, and the Russian Federation. In countries where surrogacy is prohibited, 
stakeholders have produced evidence that prospective parents may travel to other 
countries that allow commercial surrogacy.3 A third difference between countries 
relates to access to surrogacy. Since some countries require that both partners pro-
vide gametes when surrogates are used, singles are generally unable to have a child 
via surrogacy in these countries.
Finally, due to the frequent cross-border nature of surrogacy, highly contentious 
ethical and legal debates have arisen about the citizenship and parental rights of sur-
rogate and adoptive parents. The media have recently reported numerous cases of 
babies who have been left without citizenship or parents. A famous case that dem-
onstrates the legal problems that can arise is that of twins who were born to a gay 
male British couple, of whom one was the biological father, with the help of an 
anonymous egg donor and a Ukrainian surrogate mother (Henderson 2008). Because 
of conflicts between British and Ukrainian laws, the British father was not treated as 
a parent of the twins, and his children were not allowed to enter the United Kingdom. 
Conversely, the Ukrainian surrogate mother had waived all rights to custody of her 
biological offspring in a surrogacy agreement, which was, however, only recog-
nized under Ukrainian law, and not under British law. In the end, the British couple 
were able to gain custody of the twins following a decision in a British court of law. 
Similar cases have been reported in Germany: for example, babies who were born 
outside of the country using surrogacy have been denied citizenship, even though 
the German parents were named on the birth certificate (The Local 2011). Concerns 
have been raised about the “Baby Gammy” case, in which a child with Down’s 
syndrome who was born to a Thai surrogate mother was abandoned by the intended 
Australian parents. The child was recently granted Australian citizenship, and 
remains under the care of the Thai surrogate mother (Farrell 2015). The legal mech-
anisms for granting parenthood status remain unclear and differ depending on where 
the surrogate mother is located, or on a court’s opinion regarding the best interests 
3 See, e.g., Surrogacy UK, http://www.surrogacyuk.org/
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Table 14.3 Overview of legal approaches to surrogacy, Europe and selected other countries, 2013
General 
prohibition
Commercial 
surrogacy allowed 
or prohibited?
Special law on 
surrogacy?
Adoption rules or 
recognition of 
citizenship of 
children from 
cross-border 
surrogacy
Austria Egg donation 
prohibited; 
gestational 
surrogacy 
allowed
No specific 
prohibition for 
traditional 
surrogacy
No for 
traditional 
surrogacy
No recognition of 
child’s citizenship
Belarus Allowed Unknown Unknown Unknown
Belgium Allowedb Prohibited on 
public policy 
grounds
No for altruistic 
surrogacy
Adoption required 
to transfer legal 
parenthood
Bulgaria Prohibited n/a No, but draft 
legislation under 
consideration
n/a
Cyprus Allowed Allowed/no 
prohibition
Yes Surrogate mother 
and biological 
father listed on 
birth certificate
Czech 
Republic
Allowed Allowed/no 
prohibition
Yes Unknown
Denmark Allowedb Prohibited No for altruistic 
surrogacy
Adoption required 
to transfer legal 
parenthood
Estonia Allowed Allowed/no 
prohibition
Yes Unknown
Finland Prohibited for 
IVF
No specific 
prohibition for 
traditional 
surrogacy
No for 
traditional 
surrogacy
Unknown
France Prohibited n/a n/a Unknown
Germany Prohibited n/a n/a No recognition of 
child’s citizenship
Greece Allowed Allowed/no 
prohibition
Yes: altruistic 
gestational 
surrogacy 
subject to 
restrictions
Surrogate mother 
and biological 
father listed on 
birth certificate
Hungary Allowed Prohibited No for altruistic 
surrogacy
(continued)
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Table 14.3 (continued)
General 
prohibition
Commercial 
surrogacy allowed 
or prohibited?
Special law on 
surrogacy?
Adoption rules or 
recognition of 
citizenship of 
children from 
cross-border 
surrogacy
Ireland Allowedb Prohibited No for altruistic 
surrogacy but 
formal 
guidelines for 
cross-border 
surrogacy 
agreements
Adoption required 
to transfer parents; 
genetic intended 
parents’ names as 
legal parents on 
birth registry
Italy Prohibited n/a n/a/ Unknown
Latvia Allowed Prohibited No for altruistic 
surrogacy
Unknown
Lithuania Allowed Allowed/no 
prohibition
Yes Unknown
Luxembourg Allowed Allowed/no 
prohibition
Yes Unknown
Malta Prohibited n/a n/a Unknown
Norway Prohibited n/a No
Netherlands Allowedb Prohibited Yes altruistic 
gestational 
surrogacy 
required by law 
to abide by 
professional 
guidelines
No special law for 
parenthood: 
adoption required
Poland Allowed Allowed/no 
prohibition
Yes Surrogate mother 
and biological 
father listed on 
birth certificate
Portugal Prohibited n/a n/a Unknown
Russian Fed. Allowed Allowed/no 
prohibition
Unknown Unknown
Slovakia Allowed Allowed/no 
prohibition
Yes Unknown
Slovenia Allowed Allowed/no 
prohibition
Yes Unknown
Spain Prohibited n/a n/a Unknown
(continued)
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Table 14.3 (continued)
General 
prohibition
Commercial 
surrogacy allowed 
or prohibited?
Special law on 
surrogacy?
Adoption rules or 
recognition of 
citizenship of 
children from 
cross-border 
surrogacy
Sweden Prohibited for 
fertility clinics 
to make 
surrogacy 
arrangements
Prohibited No law for 
privately 
arranged 
surrogacy; 
Swedish Council 
Medical Ethics 
recently 
recommended 
altruistic 
surrogacy 
should be 
permitted
Adoption required 
to transfer 
parenthood
Switzerland Prohibited n/a n/a No recognition of 
child’s citizenship
Turkey Prohibited n/a n/a Unknown
Ukraine Allowed Allowed/no 
prohibition
Unknown Intended parents’ 
names on birth 
certificate
United 
Kingdom
Allowedb Prohibited No for altruistic 
surrogacy
Parenthood only 
transferred in 
certain 
circumstances
India Allowed Allowed/no 
prohibition
Yes Parents’ names on 
birth certificate, 
Indian surrogates 
cannot be named 
as mother
Japan Prohibited n/a n/a Unknown
Canada Allowedb Prohibited Unknown Unknown
United States Alloweda Allowed/certain 
prohibitions
Yes Parents’ names on 
birth certificate
Notes: In traditional surrogacy, the surrogate mother is the genetic mother, as one of her eggs is 
inseminated using the sperm of the intended father or donated sperm (either IVF or insemination). 
In altruistic surrogacy, the surrogate mother is paid nothing or only enough to cover her expenses. 
In commercial surrogacy, the surrogate mother is paid a fee that may exceed her expenses
Source: Brunet et al. (2013), Ory et al. (2014), Families Thru Surrogacy (2015). When expert 
interviews from IFFS data from Ory et al. (2014) differed from legal and clinical survey data 
reported by Brunet et al. (2013), the latter data were adopted over the expert interviews
aAllowed in California, Maryland, Massachusetts, Ohio, Pennsylvania, South Carolina, Alabama, 
Arkansas, Connecticut, Illinois, Iowa, Nevada, North Dakota, Oregon, Tennessee, Texas, Utah, 
and West Virginia
bAllowed only for non-commercial surrogacy (i.e., the mother is not paid or is paid only enough to 
cover her expenses)
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of the child. It appears that when many ART laws were initially written or amended, 
surrogacy was often excluded or barely acknowledged.
14.4  Cross-Border Reproductive Care in Europe
As we touched upon in our discussion on surrogate motherhood, the variation in 
regulations in Europe has given rise to the phenomenon of cross-border reproduc-
tive care (Shenfield et al. 2010; Nygren et al. 2010). Cross-border reproductive care 
refers to couples or individuals seeking assisted reproduction treatments in a coun-
try other than their country of permanent residence.4 Although practitioners, 
patients, and policy-makers appear to be aware of this phenomenon, there is little 
empirical research on the actual extent of cross-border reproductive care. The 
review article by Hudson et al. (2011) tellingly reported that the number of com-
mentaries on the topic greatly exceeds the number of empirical studies.
So far, researchers have been unable to generate reliable estimates of the inci-
dence of cross-border reproductive care. The most ambitious attempt to conduct a 
global survey of this form of care was by Nygren et al. (2010), who collected infor-
mation from experts in 23 countries. Virtually all of the reports were based on esti-
mates by informants rather than empirical data, and the authors concluded that their 
efforts yielded “little, if any, solid data” on cross-border reproductive care. The 
estimates of Nygren et al. suggest that most cross-border reproductive care in 
Europe involves traveling to other European countries, not to other continents.
The largest study of patients undergoing cross-border reproductive care in 
Europe was conducted in 2008/09 by Shenfield et al. (2010). They surveyed all 
women from other countries who were undergoing treatment in 44 fertility clinics 
in Belgium, the Czech Republic, Denmark, Switzerland, Slovenia, and Spain. The 
main countries of origin of the women seeking care were Italy (32 %), Germany 
(15 %), the Netherlands (12 %), and France (9 %). Geographic and cultural proxim-
ity is a driving factor in the choice of treatment country: the majority of Italians 
traveled to Spain and Switzerland, most of the Germans traveled to the Czech 
Republic, the majority of the Dutch and French women went to Belgium, and most 
of the Norwegian and Swedish women traveled to Denmark. Shenfield and col-
leagues suggest that a conservative estimate of cross-border reproductive care (i.e., 
crossing country borders in order to undergo ART) in 2008/2009 would be one of 
11,000–14,000 patients and 24,000–30,000 treatment cycles in the six countries 
alone. When confronted with the number of ART cycles (2008: 532,000; 2009: 
537,000) counted in all of Europe at that time (Ferraretti et al. 2012; Ferraretti et al. 
2013), this is a small, yet substantial share of patients and cycles.
4 This phenomenon is also sometimes referred to as “reproductive tourism” or “reproductive exile” 
(Pennings 2005), but given the charged nature of both terms, we follow Shenfield et al. (2010) in 
their use of the more descriptive and neutral term “cross-border reproductive care.”
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The reasons for seeking cross-border reproductive care are diverse, with patients 
reporting a combination of factors (Culley et al. 2011). The main reasons cited were 
legal restrictions, difficulties in accessing ART treatments (e.g., long waiting lists), 
the expectation of better quality treatment in the destination country, and the failure 
of previous treatments in the patient’s country of origin. A number of studies have 
described the legal reasons why ART patients seek treatment in other countries. For 
example, egg donation is a form of assisted reproduction that is banned in some 
European countries, including Germany. Thus, some German couples travel to the 
Czech Republic or Spain for egg donation (Bergmann 2011). In France, single 
women and lesbian couples lack access to donor sperm (see Table 14.2). Thus, these 
women sometimes travel to Belgium to seek treatment (van Hoof et al. 2015; Rozée 
Gomez and de La Rochebrochard 2013). Certain countries, like the United Kingdom, 
have long waiting lists for donor gametes, and patients who wish to avoid lengthy 
waiting periods seek treatment in countries where donor gametes are more readily 
available (Culley et al. 2011). These long waiting periods have arisen for a number 
of reasons. For example, some countries (e.g., Finland, Sweden, and the United 
Kingdom) have banned anonymous gamete donation, which tends to discourage 
donation. There is also considerable variation across countries in the amounts 
donors are paid. Patients from countries such as Italy hope to receive better quality 
treatments abroad (Zanini 2011; Shenfield et al. 2010), while other patients go 
abroad because the previous treatments they received in their country of residence 
failed (Shenfield et al. 2010; Culley et al. 2011). In their comparative study of 
patients seeking treatment abroad, Shenfield and colleagues (2010) found evidence 
that supports the assumption that differences in regulations are important drivers of 
cross-border fertility care. Between 57 and 80 % of patients from Italy, Germany, 
Norway, France, and Sweden cited legal restrictions as one of the reasons why they 
were seeking fertility treatment abroad. By contrast, only 32 % of patients from the 
Netherlands and 9 % of patients from the United Kingdom cited legal barriers. 
However, 53 % of patients from the Netherlands reported that they went abroad to 
obtain better quality treatment (compared to an average of 43 % across the six coun-
tries surveyed), while 34 % of the patients from the United Kingdom said they went 
abroad because of access difficulties (compared to an average of 7 % across the six 
countries surveyed).
While the extent to which European patients cross borders to obtain reproductive 
care appears to be limited, cross-border care has far-reaching consequences and 
implications for ART regulation, access, and treatment success rates. Because it is 
relatively easy and inexpensive for Europeans to travel across borders to obtain 
care, the value of legal restrictions on ART is largely symbolic (van Beers 2015). 
Furthermore, as patients can easily circumvent national regulations by seeking 
treatment abroad, patient groups and other national stakeholders may have reduced 
incentives to make their interests known in the policy-making process. This lack of 
pressure allows policy-makers to impose more onerous restrictions than they would 
have if they had been facing more resistance from stakeholders (Storrow 2010). 
Furthermore, cross-border reproductive care has implications for equity of access to 
ART. Rozée Gomez and de la Rochebrochard (2013) have reported that lower 
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income French patients seek fertility treatment in Greece for financial reasons. This 
might in turn affect access to ART within Greece, as local patients might be “priced 
out” of the market for ART services.
14.5  Discussion
This study has shown that there is marked variation in ART usage levels across 
Europe, and that the highest levels are not just in affluent countries such as Denmark 
and Belgium, but also in Slovenia, the Czech Republic, Estonia, and Serbia. The 
reasons for this variation include affordability, reimbursement levels, and the social 
and cultural norms surrounding childbearing. A striking shift has been the move 
away from IVF as the dominant form of ART, and toward ICSI, a method used pri-
marily to treat male infertility. We also show that the mix of treatments used varies 
across countries.
Currently, all of the European countries have laws on ART, and virtually all (with 
the exception of Belarus, Ireland, and Switzerland) provide some sort of financial 
assistance for treatments. The countries where the cost of treatments is completely 
covered by national health plans—such as Denmark, Slovenia, and Spain—have the 
highest ART utilization rates. Coverage also differs by patient characteristics, such 
as the age of the prospective mother and how many children she already has. In 
many countries, patients who seek ART treatments must be legally married or in a 
stable partnership. Currently only half of European countries permit single women 
to have ART treatments, and even fewer countries grant access to lesbian women.
We also looked at the increasingly relevant issue of surrogacy and cross-border 
reproductive care. Surrogacy is strictly prohibited in many countries, and where it is 
allowed, there are often restrictions on commercial surrogacy. Due to the frequent 
cross-border nature of surrogacy, there is considerable confusion about which laws 
apply when determining the citizenship of the child and the parental rights of the 
surrogate and the adoptive parents. The growth in cross-border reproductive care 
means that restrictive national regulations can be easily circumvented, but it raises 
questions about equity of access. Cross-border reproductive care is a transnational 
phenomenon that forces social scientists and policy-makers to think beyond the 
confines of the nation-state (Mau and Verwiebe 2010; Wimmer and Glick Schiller 
2002). Notwithstanding all of the problems related to patients crossing borders to 
achieve fertility treatment, it is important to acknowledge that women have been 
crossing borders in Europe for a long time to abort pregnancies, exploiting country 
differences in reproductive legislation.
Recently, there has been a rise in the uptake of techniques such as the “social 
freezing” of eggs, and it has even been suggested that ART could help countries 
raise their fertility levels. However, we would be reluctant to argue that it is an 
upcoming policy to reconcile career and family aspirations, such as measures that 
encourage flexible work schedules (Präg and Mills 2014) or improve access to pub-
lic childcare (Mills et al. 2014). Because ART treatments tend to have low success 
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rates at higher ages, they cannot be expected to reverse the “biological clock” (Präg 
et al. 2015; Wyndham et al. 2012).
This study also showed some strong limitations in what we are able to conclude, 
which is due to the lack of data about ART in Europe. In the future, researchers 
should first attempt to standardize the collection of data on ART treatments and their 
outcomes, as this would improve our knowledge of the individual antecedents and 
effects of ART. Second, researchers should develop national databases to collect 
quantitative information that can be linked across countries, as cross-border repro-
ductive care needs to be properly registered. Third, we need these initiatives to not 
only monitor cross-border reproductive care in Europe, but also to support caregiv-
ers in providing help for patients both undergoing and returning from cross-border 
fertility care in these often legally diffuse situations.
Although Europe is currently the biggest market for ART in the world, it is 
important to note that the demand for ART is relatively low in Europe. Paradoxically, 
involuntary childlessness is most prevalent (and is perceived by infertile women as 
most pressing) in Africa, where fertility levels are the highest in the world. Given 
the increasing international recognition of the problem and the push for the low-cost 
provision of ART (Ombelet 2014), the “globalization of ART” has yet to be achieved 
(Inhorn and Patrizio 2015).
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